Venous Thromboembolism (VTE) Knowledge

Status Recruiting

Clinical Trial Summary

Venous thromboembolism (VTE) is common especially among post-operative patients, and its occurrence is associated with significant morbidity and mortality. VTE is highly preventable with prophylactic modalities ranging from conservative measures such as early mobilization, to mechanical prophylaxis such as intermittent pneumatic compression (ICP), to pharmacological prophylaxis such as peri-operative anticoagulation. Despite established guidelines from various professional societies, the practice of VTE prophylaxis varied greatly from institute to institute. Evidence suggests that there is a significant gap between the optimal thromboprophylaxis as suggested by experts and real-work practice. Many healthcare-providers (HCP) and patients at risk of VTE are either not aware of the risk of VTE or not confident to apply the necessary thromboprophylaxis. The knowledge level of VTE appears to play a key role in affecting the level of compliance to the optimal thromboprophylaxis. Considerable improvement in VTE prophylaxis utilization may result from the implementation of a multifaceted educational program. By improving patient's awareness on VTE prophylaxis, the incidence of DVT might be reduced. The knowledge level of patients can be improved by various means including educational video, administrative measures, or continue medical education program. However, no prospective study has been performed to assess the impact of an educational program on the VTE knowledge level among post-operative patients and their HCP, and if any improvement of their knowledge level can be translated to a better adherence to VTE prophylaxis guidelines. We therefore propose to conduct a prospective non-randomized controlled study to evaluate the effect of an education materials for the patients as well as their HCP on their knowledge level as well as the utilization and adherence of VTE prophylaxis in these patients by comparing two groups of patients and HCP.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05548010
Study type	Observational
Source	Chinese University of Hong Kong
Contact	Daniel Xu
Phone	35051518
Email	danielxu@cuhk.edu.hk
Status	Recruiting
Phase
Start date	November 29, 2022
Completion date	November 29, 2023

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05794165` - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism	Phase 2
Active, not recruiting	`NCT05563883` - Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
Terminated	`NCT02475187` - Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
Recruiting	`NCT00982514` - Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008	N/A
Completed	`NCT01420809` - Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection	N/A
Terminated	`NCT00206089` - Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events	Phase 3
Completed	`NCT00014352` - Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer	Phase 2
Completed	`NCT00000614` - Prevention of Recurrent Venous Thromboembolism (PREVENT)	Phase 3
Active, not recruiting	`NCT05656963` - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed	`NCT04719182` - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Completed	`NCT02935751` - Apixaban Discontinuation Prior to Major Surgery
Terminated	`NCT02579122` - REVIparin-BRIDging-in a General Practice Setting in GErmany
Completed	`NCT01696760` - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology	N/A
Completed	`NCT00986154` - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).	Phase 3
Terminated	`NCT00662688` - Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer	Phase 3
Completed	`NCT00260988` - A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery	Phase 2/Phase 3
Terminated	`NCT00031837` - Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer	Phase 3
Completed	`NCT03877770` - DVT After Cardiac Procedure
Completed	`NCT00024297` - Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters	N/A
Recruiting	`NCT06118957` - Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.